A design strategy to generate a SARS‐CoV‐2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responsesChristoph Ratswohl(Max Delbrück Center), Kathrin de la Rosa(Max Delbrück Center)European Journal of ImmunologyJuly 12, 202310.1002/eji.202350408Cited by 3SaveCiteExport RISWatch citationsRelated PapersPrecise CRISPR-Cas9 gene repair in autologous memory T cells to treat familial hemophagocytic lymphohistiocytosis|Science Immunology|2024|13